NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors of antibodies, enzymes or nanoparticles. These AMFA-modified therapeutics will target patients suffering from lysosomal storage disorders, cancers, inflammatory or immune diseases.
Based on AMFA
NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA.
The main application
is the engineering of recombinant proteins like antibodies or enzymes for better therapies.
NanoMedSyn develops engineered therapeutics in-house and in partnership.